Payment overview · 2025
General Payments
$30,578.91
143 reported records · 23 companies
Healthcare provider profile · identity verified
Nirav S. Patel, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LOS ALAMITOS, CA · NPI 1881631539
Verified facts
What the public records show
CMS Open Payments records show Nirav S. Patel, M.D. received $30,578.91 in general payments during 2025 across 143 reported records.
Lundbeck LLC accounted for 52.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Leqembi.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LEQEMBI as an associated drug or biological on 4686 records involving 1817 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Leqembi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16,011.80 | 52.4% | 33 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $11,654.77 | 38.1% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $514.84 | 1.7% | 24 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $407.97 | 1.3% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $355.09 | 1.2% | 16 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$248.87 | 0.8% | 5 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $188.07 | 0.6% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $157.33 | 0.5% | 6 | 2025 |
| Janssen Research & Development, LLC | Unresolved — no canonical attribution shown | $149.36 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $144.42 | 0.5% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $130.31 | 0.4% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $114.62 | 0.4% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $95.02 | 0.3% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $65.95 | 0.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.58 | 0.2% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $59.45 | 0.2% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $52.22 | 0.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.09 | 0.1% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $29.64 | 0.1% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $29.21 | 0.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.71 | 0.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $25.68 | 0.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.91 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $14,653.92 | 16 |
| Honoraria | $11,640.00 | 4 |
| Food and Beverage | $3,293.25 | 110 |
| Travel and Lodging | $848.59 | 8 |
| Education | $143.15 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16,011.80 | 33 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $10,911.38 | 5 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $514.84 | 24 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $289.01 | 10 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $278.86 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $228.97 | 9 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $188.07 | 4 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $98.86 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $95.02 | 4 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $78.31 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $74.29 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.53 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $70.00 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $63.58 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $56.02 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $50.37 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $50.37 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $45.56 | 2 | 2025 |
Source payment records
|
|||||
| TNKase Normalized: tnkase |
Biological | Genentech USA, Inc. | $44.62 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $42.62 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $37.33 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $16.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LEQEMBI leqembi |
2025 | Leqembi | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | LEQEMBI open payments reported associated product |
CMS Open Payments — General Payments 4686 supporting records · 1817 recipient NPIs · example record 1208299730 |
Leqembi · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 102 | 29 |
| Memantine Hcl | Memantine Hcl | 94 | 23 |
| Gabapentin | Gabapentin | 78 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Modafinil | Modafinil | 34 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 31 | 12 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Armodafinil | Armodafinil | 27 | suppressed |
| Leqembi | Lecanemab-Irmb | 24 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Levetiracetam Er | Levetiracetam | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 16 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Valtoco | Diazepam | 13 | suppressed |
| Vimpat | Lacosamide | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Aubagio | Teriflunomide | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30,578.91 · 143 records | Lundbeck LLC | BOTOX, Briviact, CREXONT, Dysport, General - DBS, HYQVIA, INBRIJA, KESIMPTA, KISUNLA, LEQEMBI, NURTEC ODT, Ocrevus Zunovo, PANZYGA, PRECIVITYAD2, PURIFIED CORTROPHIN GEL, QULIPTA, Rystiggo, SPINRAZA, TNKase, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, XCOPRI, Xeomin | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Leqembi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error